



Anatara Lifesciences announces the appointment of new Non-Executive Chairman and Non-Executive Director

Anatara announces two new directors to its Board of Directors, with Sue MacLeman joining as Non-Executive Chairman and Dr. Jane Ryan as Non-Executive Director.

BRISBANE, QUEENSLAND, AUSTRALIA, August 30, 2018 /EINPresswire.com/ -- [Anatara Lifesciences](#) (ASX:ANR) is pleased to announce the appointment of two human health focused directors to the Anatara Lifesciences Board of Directors, with Sue MacLeman joining as Non-Executive Chairman and Dr. Jane Ryan as Non-Executive Director from 1 September 2018.

Pharmaceutical and biotech industry veteran, Sue MacLeman, will take over the role of Non-Executive Chairman from Dr. Jay Hetzel, who as Interim Chairman has led the Company since the retirement of Dr Mel Bridges, Co-Founder, Chairman & CEO earlier in the year.

The two new appointments follow an extensive search by the Board to identify directors with relevant background and experience following the company's commercial decision to focus on the development of products and technologies in the human gut health sector.

Dr Jay Hetzel said, "We have been very fortunate to attract two such high caliber individuals to join our Board and I am delighted to be handing over the baton to Sue MacLeman, who is well equipped to lead the Board through the next stage of the Company's development. I am confident that the newly evolved board, backed by a talented management team, has the experience and tenacity to build this Company going forward and to create lasting patient and shareholder value."

Sue MacLeman

Sue has more than 25 years' experience as a pharmaceutical, biotechnology and medical technology executive with senior roles at Schering-Plough Corporation (now Merck) Amgen, Bristol-Myers Squibb and Mesoblast. She recently stepped down from her role as Managing Director and Chief Executive Officer of the Medical Technologies and Pharmaceuticals Growth Centre (MTPConnect) where she will take up the role of Non-Executive Chairman later in the year. Sue brings a unique set of experiences in technology commercialisation, strategic planning, capital markets and fund raising, M&A and alliance management.

"I am delighted to be joining Anatara at such an exciting time. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications and this is a significant market opportunity which will be of interest to investors and patients," said Sue MacLeman.

Dr Jane Ryan

Jane has over 25 years of international experience in the pharmaceutical and biotechnology industries where she has managed research and development programs and held key roles in business development and alliance management. Jane has worked both in Australia and internationally with companies including Peptech, Roche, Cambridge Antibody Technology and Biota Holdings. Throughout her career, she has led many successful fundraising campaigns including the awarding of a \$230m US Government contract. Jane currently chairs the Advisory

Board at the ithree Institute at the University of Technology Sydney (UTS), which studies how microbes grow, live, adapt and survive.

As a result of these appointments, Paul Grujic will stand down on 31 August 2018 from the Anantara Board and also Dr Jay Hetzel has indicated he will retire as a Director at the AGM in November 2018 following a successful handover to the new Chair. Iain Ross, non-executive director and Dr. Tracie Ramsdale, who is currently Acting CEO will remain on the Anantara Board. An extensive search to identify a new CEO, with relevant experience is underway.

Ends

For more information please contact:

Cherie Hartley
IR Department
+61 (0) 418 737 020
cherie.hartley@irdepartment.com.au

About Anantara Lifesciences

Anantara Lifesciences (ASX: ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anantara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anantara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com.

Cherie Hartley
IR Department
0418737020
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.